Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

Carfilzomib Dexamethasone(40) Lenalidomide

Description: Chemotherapy Protocol MYELOMA Carfilzomib -Lenalidomide -Dexamethasone Regimen • Myeloma – Carfilzomib-Lenalidomide-Dexamethasone Indication • Carfilzomib in combination with lenalidomide and dexamethasone is an
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Carfilzomib-Dexamethasone40-Lenalidomide.pdf

WDES annual report 2022

Description: Workforce Disability Equality Standard - Annual Report 2022 2 Executive Summary The Workforce Disability Equality Standard (WDES) is a set of te
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/Workforce-Disability-Equality-Standard-Annual-Report-2022.docx

Azacitidine(SC)-Venetoclax

Description: Chemotherapy Protocol Acute Myeloid Leukaemia AZACITIDINE (SC) - VENETOCLAX Regimen  AML – Azacitidine (SC) - Venetoclax Indication  Newly diagnosed acute myeloid leukaemia (AML).  Patient
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/AzacitidineSC-Venetoclax.pdf

Enhanced recovery after elective caesarean section - patient information

Description: This leaflet contains information about the recovery process after having a planned (elective) caesarean section.
Url: /Media/UHS-website-2019/Patientinformation/Pregnancyandbirth/Enhanced-recovery-after-elective-caesarean-section-1130-PIL.pdf

Aria ePrescribing v13.6 MR1.2 user training guide

Description: Aria E-Prescribing v13.6 MR1.2 User Training Guide Every effort has been made to ensure that the material in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/User-guides/Aria-ePrescribing-v13.6-MR1.2-user-training-guide.pdf

Choosing where to have your baby - patient information

Description: Choosing where to have your baby Contents Introduction 3 Home birth 4 Birth centres 7 New Forest Birth Centre 8 Broadlands
Url: /Media/UHS-website-2019/Patientinformation/Pregnancyandbirth/Choosingwheretohaveyourbaby.pdf

ObinutuzumabVenetoclax LowRisk

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia Obinutuzumab-Venetoclax (Low Risk) Regimen • CLL – Obinutuzumab-Venetoclax (Low Risk) Indication • Chronic lymphatic leukaemia (CLL) or
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/ObinutuzumabVenetoclax-LowRisk.pdf

Blinatumomab

Description: Chemotherapy Protocol Acute lymphoblastic leukaemia (ALL) Blinatumomab (3, 4 day) Regimen • ALL – Blinatumomab (3, 4 day schedule) Indication • Treatment of Philadelphia
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Blinatumomab.pdf

VAC31518COV2001_UK_Parent and Guardian ICF_V2.0_15Feb2021_Clean Localised (1)

Description: Southampton NIHR Clinical Research Facility University Hospital Southampton NHS Foundation Trust C Level West Wing, Mailpoint 218 Southampton SO16 6YD Tel
Url: /Media/Southampton-Clinical-Research/Downloads/VAC31518COV2001-UK-Parent-and-Guardian-ICF-V2.0-15Feb2021-Clean-Localised-1.pdf

VAC31518COV2001_UK_Young Person_ Patient Information Sheet ICF_V2.0_15Feb2021_Clean Localised (3)

Description: Southampton NIHR Clinical Research Facility University Hospital Southampton NHS Foundation Trust C Level West Wing, Mailpoint 218 Southampton SO16 6YD Tel
Url: /Media/Southampton-Clinical-Research/Downloads/VAC31518COV2001-UK-Young-Person-Patient-Information-Sheet-ICF-V2.0-15Feb2021-Clean-Localised-3.pdf

661 to 670 of 672

Previous … 64 65 66 67 68 Next